These findings suggest that anti-neoplastic drugs drive CAV1 expression, leading to aggressive and metastatic phenotypes, with the implication that non-lethal concentrations of cancer drugs may actually drive, rather than inhibit, tumor progression. This evidence concerns the gene CAV1 and cancer.